The fact that nuclear ESRP1 and ESRP2 overexpression were strongly associated with unfavorable prostate cancer phenotype and poor patient outcome is in line with previous studies describing a link of high ESRPs expression and an unfavorable phenotype in breast [10, 15] and ovarian cancer [11]. This evidence concerns the gene ESRP1 and prostate cancer.